Author

Miroslav Boudný

Observed names: M. Boudny, Miroslav Boudny

Institutions: Masaryk University, Central European Institute of Technology – Masaryk University, University Hospital Brno

Observed institutions: Masaryk University, Central European Institute of Technology – Masaryk University, University Hospital Brno

ORCID: 0000-0001-5757-0424

Observed ORCID: 0000-0001-5757-0424

OpenAlex ID: A5079012544

ATR-CHK1 pathway as a therapeutic target for acute and chronic leukemias

2020 · Miroslav Boudny, Martin Trbusek · Cancer Treatment Reviews · 40

Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells

2019 · Miroslav Boudny, Jana Zemanova, et al. · Haematologica · 26

Computational Design of Pore-Forming Peptides with Potent Antimicrobial and Anticancer Activities

2024 · Rahul Deb, Marcelo D. T. Torres, et al. · Journal of Medicinal Chemistry · 24

Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides

2022 · Prashant Khirsariya, Patrik Pospíšil, et al. · Journal of Medicinal Chemistry · 13

The Important Role of STAT3 in Chronic Lymphocytic Leukaemia Biology

2020 · Miroslav Boudný, Martin Trbušek · Klinicka onkologie · 11

PDF

Stromal cells engineered to express T cell factors induce robust CLL cell proliferation in vitro and in PDX co-transplantations allowing the identification of RAF inhibitors as anti-proliferative drugs

2024 · Eva Hoferkova, Vaclav Seda, et al. · Leukemia · 8

PDF

Duplication of 8q24 in Chronic Lymphocytic Leukemia: Cytogenetic and Molecular Biologic Analysis of MYC Aberrations

2022 · Eva Ondroušková, Michaela Bohúnová, et al. · Frontiers in Oncology · 4

Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphoma

2026 · Daniel Filip, Katerina Litzmanova, et al. · Leukemia · 1

PDF

81 | REPRESSION OF miR‐29 VIA MYC LEADS TO INCREASED CD40 SIGNALING IN TRANSFORMED FOLLICULAR LYMPHOMA (FL) AND UNFAVOURABLE PROGNOSIS IN FL

2025 · D. Filip, K. Litzmanova, et al. · Hematological Oncology

PDF

Analysis of extracellular vesicles of frequently used colorectal cancer cell lines

2025 · Marie Boudná, Nicolas Blavet, et al. · BMC Cancer

Pf361 Atr-chk1 Signaling Is Active and Targetable in Quiescent Cll Cells

2019 · M. Boudny, P. Khirsariya, et al. · HemaSphere

Potencial inhibice proteinu checkpoint kinase 1 u chronicke lymfocytarni leukemie s mutacemi v genu TP53.

2019 · Miroslav Boudný, Jana Zemanová, et al.

Selective CHK1 inhibitor MU380 exhibits single-agent activity against chronic lymphocytic leukemia cells with TP53 mutations

2018 · Miroslav Boudný, Jana Zemanová, et al.

Inovativní inhibitor proteinu CHK1 indukuje apoptózu u buněk chronické lymfocytární leukémie s mutacemi v genu TP53

2018 · Miroslav Boudný, Jana Zemanová, et al.

Potenciál inhibice proteinu Chk1 u chronické lymfocytární leukémie s mutacemi v genu TP53.

2017 · Miroslav Boudný, Jana Zemanová, et al.

ATR-Chk1 pathway as a therapeutic target for leukemia and lymphoma

2017 · Miroslav Boudný, Alexandra Oltová, et al.

Potenciál inhibice proteinu Checkpoint kinase 1 u B-buněčných malignit

2016 · Miroslav Boudný

Chronic lymphocytic leukemia cells are highly susceptible to direct inhibition of checkpoint kinase

2015 · Jana Zemanová, Kamil Paruch, et al.

Testování protinádorové terapie na buňkách chronické lymfocytární leukémie s mutacemi v genech TP53 a ATM

2014 · Miroslav Boudný

Works count: 19

Citation count: 127

H-index: 6

I10-index: 5